The introduction of Retatrutide ZPHC, at a concentration of 120mg, is sparking considerable buzz within the healthcare community. This groundbreaking dual GIP and GLP-1 receptor medication suggests to deliver significant improvements in weight loss compared to current therapies. Early research studies have demonstrated significant reductions in bod